MBio Diagnostics is developing a portfolio of innovative tests for remote settings where lab-quality results are vital in making time-critical decisions.
The LightDeck® platform was designed to meet customer requirements:
- Quality: Highly sensitive tests that deliver lab-quality results
- Quick: Actionable data in 5-15 minutes with a simple procedure
- Quantitative: More than yes/no to inform treatment decisions
- Multiplex: Multiple tests per sample plus internal quality control to maximize confidence in results
The LightDeck COVID-19 Total Antibody Test is to determine past SARS-CoV-2 infection and potential immunity.
Host-response biomarkers in acute infection can help stage patients and inform treatment decisions.
We are developing a NextGen test for heart attack: a high-sensitivity troponin test and a 3-plex Cardiac Panel.
MBio offers tests for toxins associated with harmful algae bloom.